GW 282974
Latest Information Update: 02 Aug 2023
At a glance
- Originator GlaxoSmithKline
- Class Antineoplastics
- Mechanism of Action Protein tyrosine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Breast cancer; Non-small cell lung cancer
Most Recent Events
- 25 Jan 2001 No-Development-Reported for Breast cancer in United Kingdom (Unknown route)
- 25 Jan 2001 No-Development-Reported for Breast cancer in USA (Unknown route)
- 25 Jan 2001 No-Development-Reported for Non-small cell lung cancer in United Kingdom (Unknown route)